drugset / Trial / NCT01491529
Evaluation of the Efficacy and Safety of Modified Release AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study will assess the efficacy and safety of modified release AFQ056 in patients that have Parkinson's Disease L-dopa Induced Dyskinesias (PD-LID)
Timeline
- Start
- 2012-04
- Primary completion
- 2013-04
- Completion
- 2013-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mavoglurant | Small molecule | 150 mg | Oral |
| Subject | Mavoglurant | Small molecule | 200 mg | Oral |